The trial – a randomized, double-blind, placebo-controlled, parallel group, dose-escalation study of intravenously administered ACHN-490 – is supported by the GBP4.1 million seeding drug discovery award received from the Wellcome Trust, as announced by the company in January 2009.
Kevin Judice, CEO of Achaogen, said: “We are very pleased that a promising neoglycoside compound discovered at Achaogen is being studied in our first clinical trial.
“We expect this initial clinical study of ACHN-490 to inform the dosing and trial design of our Phase II study in complicated urinary tract infection, as well as additional future studies addressing complicated intra-abdominal infections, bloodstream infections and other serious, unmet medical needs in the hospital setting. We expect to complete this trial in 2009, and initiate a Phase II study in early 2010.”